To be the European leader in pharmaceutical products for
the treatment of the central nervous system (CNS)
To offer a wide range of proven, differentiated and affordable
CNS treatment options to patients, healthcare professionals and industry partners
– based on our in-depth knowledge of the differentiated CNS markets in the different European countries
Consolidated as a group in 2016, Neuraxpharm has a unique understanding of the CNS market of more than 30 years.
Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals and nutraceuticals, offering a wide range of effective, differentiated and affordable CNS treatments, aimed at patients as well as health professionals and industry partners.
Additionally, through our manufacturing companies Lesvi and Inke, Neuraxpharm has an international presence in more than 50 countries. We provide industry partners with finished dosage forms (FDFs) across multiple technologies and niche active pharmaceutical ingredients (APIs) using our expertise in the CNS and the respiratory areas.
with sales forces in our main EU markets to strengthen our international position as a leader in CNS
into a robust pipeline that broadens our CNS portfolio with differentiated products
with the European community of CNS patients and healthcare professionals
from our international portfolio through the B2B selling of FDFs and APIs
via backward integration and strengthening operational excellence within the company
with a strong focus on quality, collaboration and agility promoting smart solutions that differentiate us from our competitors
Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals related to the prevention of CNS indications in main European countries
Neuraxpharm also owns and operates two manufacturing plants in Spain
Global presence through selling APIs and FDFs to more than 50 countries